Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017 | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017


We issued an updated research report on Cambridge, MA-based Sarepta Therapeutics, Inc. SRPT on Jun 28.

Sarepta is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases, especially Duchenne muscular dystrophy (DMD).

So far this year, Sarepta’s share price has outperformed the Zacks categorized Medical-Biomed/Genetics industry. The stock has surged 21.6% compared with an increase of 10.0% for the broader industry.

https://www.duchennexchange.org/wp-content/uploads/2017/07/sareta.jpg